Clinical trials: Prophylactic
Migraine
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
- Trial name
- NCT02621931
- Testing
- Fremanezumab
- Where
- 273 sites in United States, Canada and 7 more
- Volunteers
- 1,130 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hereditary Angioedema
A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE
The objectives of the study were: 1. To assess the safety and tolerability of escalating doses of CINRYZE. 2. To assess the effect of an escalating dose algorithm for CINRYZE on hereditary angioedema (HAE) attack rates. 3.
- Trial name
- NCT00914966
- Testing
- C1 inhibitor (human) [C1 INH]
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Shire
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
- Trial name
- NCT02629861
- Testing
- Fremanezumab
- Where
- 275 sites in United States, Canada and 7 more
- Volunteers
- 875 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
This trial is conducted in Africa, Asia, Europe and North America. The aim of the trial is to assess the efficacy of concizumab administered s.c.
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- explorer™4 (NCT03196284)
- Testing
- Concizumab, Eptacog alfa
- Where
- 22 sites in United States, Austria and 12 more
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector
The purpose of this study is to compare the safety, tolerability and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) [previously DENVax] when administered intradermally in varied dosing schedules and via…
- Trial name
- NCT01765426
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Takeda
Hepatitis B
A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™
Each Sci-B-Vac™ lot to be released to the market is tested in comparison to a reference batch,which has to be tested in a human clinical trial. This study was conducted by SciVac Ltd.
- Trial name
- NCT04179786
- Testing
- Sci-B-Vac™
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Hemophilia
A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions
The main aim is to describe how the treatment burden and challenges of participants, relatives, and doctors during regular Factor VIII and Factor IX infusions to treat hemophilia evolve using a virtual-reality (VR) based…
- Trial name
- NCT05437211
- Testing
- Virtual-reality (VR) Based Solution
- Where
- 6 sites in France
- Volunteers
- 24 people
- Sponsor
- Takeda
Influenza
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
- Trial name
- NCT05523089
- Testing
- CD388
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Subjects Scheduled to Undergo Laparoscopic Radical Resection of Rectal Carcinoma With Preventive Ileostomy
Prospective, Multicenter, Randomized Controlled Study to Evaluate the Effect of INTERCEED™
This is a prospective, randomized controlled study. The study population will include 220 subjects scheduled to undergo laparoscopic radical resection of rectal carcinoma with preventive ileostomy (Phase 1 operation).
- Trial name
- NCT03462563
- Testing
- INTERCEED™
- Where
- 12 sites in China
- Volunteers
- 175 people
- Sponsor
- Ethicon, Inc.
Cataract
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
- Trial name
- NCT00870103
- Testing
- Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Stomach Ulcer, Duodenal Ulcer
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
The purpose of this study is to determine whether lansoprazole, once daily (QD), compared to gefarnate, twice daily (BID), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term…
- Trial name
- NCT00762359
- Testing
- Lansoprazole, Gefarnate
- Where
- 65 sites in Japan
- Volunteers
- 461 people
- Sponsor
- Takeda
Migraine
Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine
The primary objective of this study is to evaluate the treatment benefit of erenumab on headache duration of at least moderate pain intensity.
- Trial name
- EMBRACE (NCT04252742)
- Testing
- Erenumab
- Where
- 91 sites in United States, Bulgaria and 7 more
- Volunteers
- 512 people
- Sponsor
- Amgen
Migraine
Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment.
- Trial name
- NCT04828707
- Testing
- Nerivio active device
- Where
- 16 sites in United States
- Volunteers
- 335 people
- Sponsor
- Theranica
Chronic Migraine
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound.
- Trial name
- ATO-BOTOX (NCT05216263)
- Testing
- Atogepant
- Where
- 29 sites in United States
- Volunteers
- 75 people
- Sponsor
- AbbVie
Preventive Medicine, Multi Organ Failure
Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA
A study to assess effectiveness and safety of a drug FP-1201-lyo (Recombinant Human Interferon Beta-1a) in the Prevention of Multi-Organ Failure on patients after Open Surgery for a Ruptured Abdominal Aortic Aneurysm
- Trial name
- INFORAAA (NCT03119701)
- Testing
- Interferon Beta-1A
- Where
- 9 sites in Estonia, Finland and 1 more
- Volunteers
- 40 people
- Sponsor
- Faron Pharmaceuticals Ltd
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age
The primary objective of the study is to evaluate the effectiveness of fremanezumab as compared to placebo for the preventive treatment of chronic migraine (CM).
- Trial name
- NCT04464707
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 292 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
HIV-1, HIV Infections
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
The goal of this study is to understand the safety, tolerability and immunogenicity of the Merck Trivalent Adenovirus Serotype 5 HIV-1 gag/pol/nef Vaccine (MRKAd 5 HIV-1 gag/pol/nef) vaccine in healthy human volunteers compared…
- Trial name
- NCT00849680
- Testing
- Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose), Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
- Volunteers
- 317 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Embolism, Deep Vein Thrombosis
The Angel® Catheter Pivotal Clinical Trial
The primary objective of this multicenter, prospective, single arm clinical trial is to evaluate the safety and effectiveness of the Angel® Catheter in subjects at high risk of PE, and with recognized contraindications to…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism, Trauma
- Trial name
- NCT02186223
- Testing
- The Angel® Catheter
- Where
- 21 sites in United States
- Volunteers
- 172 people
- Sponsor
- BiO2 Medical
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.